PacBio Joins the 1000 Genomes Long Read Project to Add Isoform Sequencing with Kinnex and Revio
PacBio (NASDAQ: PACB) has joined the 1000 Genomes Long Read Sequencing Project to contribute long-read transcriptome data using its Kinnex RNA kits and Revio sequencing platform. The project will sequence approximately 1,000 samples from the 1000 Genomes cohort to provide transcript-level insights across diverse human populations.
In collaboration with researchers from the University of Washington and Johns Hopkins University, the project aims to generate around 10 million full-length transcript reads per sample. The initiative will create an open-access RNA resource and develop bioinformatics pipelines to support long-read transcriptomics research, with early findings to be presented at the upcoming ASHG conference.
PacBio (NASDAQ: PACB) ha aderito al progetto 1000 Genomes Long Read Sequencing Project per fornire dati di trascrittoma a lettura lunga utilizzando i suoi kit Kinnex RNA e la piattaforma di sequenziamento Revio. Il progetto prevede di sequenziare circa 1.000 campioni della coorte 1000 Genomes per offrire approfondimenti a livello di trascritti in diverse popolazioni umane.
In collaborazione con ricercatori dell'Universit脿 di Washington e della Johns Hopkins University, l'iniziativa mira a generare circa 10 milioni di letture di trascritti a lunghezza completa per campione. Il progetto creer脿 una risorsa RNA ad accesso aperto e svilupper脿 pipeline bioinformatiche per supportare la ricerca sulla trascrittomica a lettura lunga, con i primi risultati che saranno presentati alla prossima conferenza ASHG.
PacBio (NASDAQ: PACB) se ha unido al Proyecto de Secuenciaci贸n de Lecturas Largas de 1000 Genomas para aportar datos de transcriptoma de lectura larga utilizando sus kits Kinnex RNA y la plataforma de secuenciaci贸n Revio. El proyecto secuenciar谩 aproximadamente 1,000 muestras de la cohorte 1000 Genomes para ofrecer perspectivas a nivel de transcripto en diversas poblaciones humanas.
En colaboraci贸n con investigadores de la Universidad de Washington y la Universidad Johns Hopkins, el proyecto tiene como objetivo generar alrededor de 10 millones de lecturas de transcritos de longitud completa por muestra. La iniciativa crear谩 un recurso de ARN de acceso abierto y desarrollar谩 pipelines bioinform谩ticos para apoyar la investigaci贸n en transcript贸mica de lectura larga, con los primeros hallazgos que se presentar谩n en la pr贸xima conferencia ASHG.
PacBio (NASDAQ: PACB)电� Kinnex RNA 韨ろ姼鞕� Revio 鞁滍��鞁� 頂岆灚韽�鞚� 靷毄頃橃棳 鞛リ赴 鞚疥赴 鞝勳偓觳� 雿办澊韯半ゼ 鞝滉车頃橁赴 鞙勴暣 1000 瓴岆唸 鞛リ赴 鞚疥赴 鞁滍��鞁� 頂勲鞝濏姼鞐� 彀胳棳頄堨姷雼堧嫟. 鞚� 頂勲鞝濏姼电� 雼れ枒頃� 鞚戈惮 歆戨嫧鞐愳劀 鞝勳偓觳� 靾橃鞚� 韱奠鞍霠レ潉 鞝滉车頃橁赴 鞙勴暣 1000 瓴岆唸 旖旐樃韸胳棎靹� 鞎� 1,000臧� 靸橅攲鞚� 鞁滍��鞁表暊 鞓堨爼鞛呺媹雼�.
鞗岇嫳韯� 雽�頃欔祼鞕� 臁挫姢 頇夗偍鞀� 雽�頃欔祼 鞐瓣惮歆勱臣 順戨牓頃橃棳, 鞚� 頂勲鞝濏姼电� 靸橅攲雼� 鞎� 1,000毵� 臧滌潣 鞝勳泊 旮胳澊 鞝勳偓觳� 鞚疥赴毳� 靸濎劚頃樀鐢 瓴冹潉 氇╉憸搿� 頃╇媹雼�. 鞚� 鞚措媹靺旐嫲敫尩鐢 瓿店皽 鞝戧芳 RNA 鞛愳洂鞚� 毵岆摛瓿� 鞛リ赴 鞚疥赴 鞝勳偓觳错暀 鞐瓣惮毳� 歆�鞗愴晿旮� 鞙勴暅 靸濍鞝曤炒頃� 韺岇澊頂勲澕鞚胳潉 臧滊皽頃� 鞓堨爼鞚措┌, 齑堦赴 瓴瓣臣电� 雼り皜鞓さ鐢 ASHG 頃欗殞鞐愳劀 氚滍憸霅� 鞓堨爼鞛呺媹雼�.
PacBio (NASDAQ : PACB) a rejoint le projet 1000 Genomes Long Read Sequencing Project pour fournir des donn茅es de transcriptome 脿 lecture longue en utilisant ses kits Kinnex RNA et la plateforme de s茅quen莽age Revio. Le projet pr茅voit de s茅quencer environ 1 000 茅chantillons de la cohorte 1000 Genomes afin d'offrir des perspectives au niveau des transcrits 脿 travers diverses populations humaines.
En collaboration avec des chercheurs de l'Universit茅 de Washington et de l'Universit茅 Johns Hopkins, le projet vise 脿 g茅n茅rer environ 10 millions de lectures de transcrits en longueur compl猫te par 茅chantillon. L'initiative cr茅era une ressource ARN en libre acc猫s et d茅veloppera des pipelines bioinformatiques pour soutenir la recherche en transcriptomique 脿 lecture longue, avec les premiers r茅sultats qui seront pr茅sent茅s lors de la prochaine conf茅rence ASHG.
PacBio (NASDAQ: PACB) hat sich dem 1000 Genomes Long Read Sequencing Project angeschlossen, um Lang-Read-Transkriptomdaten mit seinen Kinnex RNA-Kits und der Revio-Sequenzierungsplattform beizutragen. Das Projekt wird etwa 1.000 Proben aus der 1000 Genomes-Kohorte sequenzieren, um transkriptbezogene Einblicke in verschiedene menschliche Populationen zu erm枚glichen.
In Zusammenarbeit mit Forschern der University of Washington und der Johns Hopkins University zielt das Projekt darauf ab, etwa 10 Millionen Voll-L盲nge-Transkript-Lesungen pro Probe zu erzeugen. Die Initiative wird eine offene RNA-Ressource schaffen und bioinformatische Pipelines entwickeln, um die Forschung im Bereich der Lang-Read-Transkriptomik zu unterst眉tzen. Erste Ergebnisse werden auf der kommenden ASHG-Konferenz pr盲sentiert.
- Partnership with prestigious research institutions (University of Washington and Johns Hopkins University)
- Creation of an open-access RNA resource for the scientific community
- Project will generate approximately 10 million full-length transcript reads per sample
- Strengthens PacBio's position in the long-read sequencing market
- None.
Insights
PacBio's partnership in the 1000 Genomes project significantly expands their Iso-Seq technology's market positioning and scientific validation.
This collaboration with prestigious research institutions positions PacBio as a key contributor to one of the world's most significant genomic initiatives. The company will leverage its Kinnex RNA kits and Revio platform to generate isoform sequencing data across approximately 1,000 samples, creating a comprehensive transcriptomic dataset.
The technical specifications are substantial - each sample is expected to yield ~10 million full-length transcript reads, representing significant sequencing depth. This demonstrates the scalability of PacBio's HiFi technology for large population studies and validates its application in transcript-level analysis.
From a strategic perspective, this partnership accomplishes several objectives for PacBio: it showcases their technology's capabilities in a high-profile scientific setting, expands their footprint in the transcriptomics market, and potentially drives future adoption of their platforms in both research and clinical settings.
The commitment to open data sharing and public availability of sequencing results and analysis pipelines suggests this project will generate reference datasets that could become standards in the field. For PacBio, this means their technology becomes embedded in fundamental research infrastructure, creating downstream opportunities as researchers develop applications based on these reference datasets.
By focusing on transcriptome analysis across diverse populations, this project aligns with the growing emphasis on inclusive genomic research and personalized medicine, potentially expanding PacBio's addressable market in emerging applications requiring comprehensive transcript characterization.
New Iso-Seq data from ~1,000 samples to expand transcriptomic insights using highly accurate HiFi sequencing
MENLO PARK, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced it has joined the 1000 Genomes Long Read Sequencing Project, which will involve contributing long-read transcriptome data to one of the world鈥檚 most expansive human genomics initiatives.听In collaboration with the laboratories of Danny Miller, MD, PhD, Evan Eichler, PhD, at the University of Washington, and Rajiv McCoy, PhD at the McCoy Lab at Johns Hopkins University, PacBio will contribute full-length isoform sequencing using its Kinnex RNA kits and Revio sequencing platform.
The collaboration will add Iso-Seq data for approximately 1,000 samples from the 1000 Genomes cohort, offering new transcript-level views across a globally diverse and deeply characterized human population. By expanding the functional layer of this foundational reference, the project aims to support more accurate interpretation of gene expression, splicing, and regulatory elements across populations and to provide a shared resource for tool development and benchmarking for the broader genetics community.
鈥淎dding full-length isoform sequencing to the 1000 Genomes Project represents a unique opportunity to enrich this foundational resource,鈥� said Dr. Miller, Assistant Professor at the University of Washington and lead investigator of the project. 鈥淭his effort will deliver a dataset and analysis framework that supports diverse applications, from basic biology to rare disease diagnostics. By integrating isoform-level information, we鈥檒l be better positioned to understand gene regulation, alternative splicing, and the transcriptomic complexity that underlies human health and disease.鈥�
Sequencing is being carried out on 1,000 cell lines using PacBio鈥檚 Kinnex RNA kits and Revio long-read platform, with each sample expected to yield around 10 million full-length transcript reads. Work is underway at both the Eichler Lab at the University of Washington and the Seattle Children鈥檚 Research Institute, with additional analysis support from the McCoy Lab at Johns Hopkins University. Together, the collaborators aim to deliver a high-quality, open-access RNA resource and build scalable bioinformatics pipelines to support the fast-growing long-read transcriptomics field.
鈥淚soform sequencing is one of the most powerful applications of our HiFi technology,鈥� said David Miller, Vice President of Global Marketing at PacBio. 鈥淲e are incredibly excited to support this important initiative with our partners at the University of Washington and Seattle Children鈥檚. This collaboration underscores the value of long-read sequencing in understanding human biology and brings us closer to realizing the full potential of long-read genomes and transcriptomes.鈥�
In addition to generating new scientific insights, the project prioritizes transparency, open data, and tool development. All sequencing data and analysis pipelines will be made publicly available to promote reproducibility and accelerate downstream research. The group plans to present early findings from this work at the upcoming American Society of Human Genetics (ASHG) conference.
This effort continues the 1000 Genomes Long Read Sequencing Project鈥檚 commitment to building open and globally representative genomic resources to advance equity, access, and innovation in human genetics research.
For more information about the 1000 Genomes Long Read Project, visit .
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit and follow @PacBio.听
听听
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.听
Forward-Looking Statements听听听
This press release contains 鈥渇orward-looking statements鈥� within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, advantages, quality or performance of, the benefits or expected benefits of using, PacBio products or technologies, including in connection with the 1000 Genomes Long Read Sequencing Project by providing isoform sequencing data from the 1000 Genomes cohort; being better positioned to understand gene regulation, alternative splicing and transcriptomic complexity; delivering resources and building pipelines; public availability of sequencing data and analysis pipelines; fast-growing long-read transcriptomics field; realizing the potential of long-read genomes; and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause actual outcomes and results to differ materially from currently anticipated results. These risks include, but are not limited to, risks inherent in developing and commercializing new technologies; rapidly changing technologies and extensive competition in genomic sequencing; unanticipated increases in costs or expenses; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights; and other risks associated with general macroeconomic conditions and geopolitical instability. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption 鈥淩isk Factors.鈥� These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
About the Miller Lab
The Miller Lab at the University of Washington focuses on advancing genomics in clinical diagnostics, particularly in the context of rare diseases. The lab is committed to developing tools and resources that democratize access to cutting-edge genomic technologies.
Contacts (Miller Lab)听
听
Danny E. Miller
[email protected]
Contacts (PacBio)听
Investors:听听
Todd Friedman听
[email protected]听
Media:听
[email protected]听
FAQ
What is PacBio's role in the 1000 Genomes Long Read Project?
How many samples will PACB sequence in the 1000 Genomes project?
Who are the key collaborators in PacBio's 1000 Genomes project?
When will the results of PacBio's 1000 Genomes project be presented?
Will the PacBio 1000 Genomes project data be publicly available?
